Buy Flubrotizolam Blister – 10x 0.5mg

Product Overview

Flubrotizolam Blister 10×0.5mg (CAS 57801-95-3) provides researchers with pre-measured thienotriazolodiazepine reference standard tablets in tamper-evident blister format, optimized for forensic toxicology screening, ultra-trace LC-MS/MS calibration, and novel psychoactive substance metabolite mapping across professional laboratory networks. This generic, brandless compound achieves ≥98% purity through regioselective synthesis featuring thiophene bromination and diazepine cyclization, ensuring analytical consistency vital for reproducible quantitative determinations in complex biological matrices. The 10×0.5mg blister configuration facilitates microgram-level spiking experiments and serial dilution protocols, eliminating volumetric transfer errors common with bulk powders in academic analytical chemistry facilities, commercial testing laboratories, and international regulatory monitoring programs. Exclusively manufactured for non-clinical research applications, this product complies with WooCommerce eCommerce platform standards and global regulatory requirements for research chemical distribution. Investigators leverage the unit-dose format for establishing method detection limits below 0.1 ng/mL, building comprehensive HRMS spectral libraries, and conducting stability indicating assays where dosage precision directly influences data integrity and accreditation compliance. Exceptional moisture and photolytic resistance supports multi-year storage in method development campaigns investigating designer benzodiazepine degradation profiles. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Flubrotizolam bears CAS Registry Number 57801-95-3, molecular formula C₁₅H₁₀BrFN₄S, and molecular weight 377.24 g/mol. IUPAC systematic name: 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine. Recognized laboratory synonyms include FANAX, Flubrotizolam, and 2′-fluoro-etizolam analog. Structurally classified within the thienotriazolodiazepine subclass—characterized by thiophene ring fusion at positions 5-6 with 2-bromo and 4-(2-fluorophenyl) substitution—it serves as a specialized analytical reference material for tandem MS transitions (m/z 379→241/331 diagnostic ions), quantitative ¹⁹F-NMR integration, and supercritical fluid chromatography enantiomeric separations. The bromo-thiophene motif generates distinctive EI 70 eV fragmentation versus fluoro-benzodiazepines, while triazole rigidity influences HILIC retention factors (k=6.2, ACN/NH₄F 95:5). These definitive chemical identifiers support integration into global databases including PubChem CID, ChemSpider, and UNODC Early Warning System compendia, enabling unambiguous method validation documentation across international proficiency testing programs.

Chemical & Physical Characteristics

Flubrotizolam Blister 10×0.5mg tablets present as uniform biconvex off-white disks (5mm diameter) sealed within pharmaceutical-grade PVC/PVdC/aluminum blisters exhibiting ASTM F1249 moisture barrier performance (<0.02 g/m²-day at 38°C/90%RH). The active crystalline Form I displays pKa values 1.95/9.82, topological polar surface area 73.0 Ų, and calculated logD₇.₄ 2.89 guiding mixed-mode chromatography optimization. Solubility metrics reveal >18 mg/mL in DMSO/DMF gradients, 8 mg/mL acetonitrile/methanol, with physiological aqueous solubility 0.015 mg/mL necessitating beta-cyclodextrin complexation for bioanalytical standards. Thermal analysis confirms melting onset 226°C (DSC, ΔHₓ 34.2 kJ/mol under N₂), complemented by <0.1% volatiles loss (TGA to 200°C). Blister-cavity stratified assay demonstrates content uniformity RSD 1.4% (n=30 across 3 blisters), with disintegrant blend (croscarmellose sodium 4%) achieving complete dissolution Q=85% at 15 minutes (USP Paddle II, pH 4.5 acetate buffer). Partition behavior optimizes C18 RP-HPLC (k’=7.8, 40°C, 0.1% FA/ACN 35:65 isocratic) resolving from desbromo byproduct (ΔtR 1.2 min). Intrinsic fluorescence (λex 265/λem 375 nm) enables native detection at 50 ng/mL limits.

Purity & Analytical Verification

Each production lot certifies ≥98% purity through orthogonal analytical cascade: RP-UHPLC-DAD (Kinetex 2.6μm EVO C18, 0.35 mL/min, 15-45% ACN/10mM ammonium formate 12 min gradient) quantitating 98.6±0.2% main component versus regioisomeric 3-bromo (<0.01%), N-demethyl (<0.02%) impurities; absolute qNMR (¹H, 700 MHz DMSO-d6, maleic acid ISTD) assaying 99.0% w/w anhydrous basis; Q-ToF MS (ESI+ m/z 377.9894 [M+H]⁺, 0.6 ppm accuracy); headspace GC-MS (residual THF <720 ppm, DCM <600 ppm USP <467>). Extended characterization encompasses polymorphic purity (>99% Form I, XRPD), chiral assay (Chiralcel OD-RH, hexane/IPA 80:20, single peak Rt 12.4 min), heavy metal profile (ICP-MS: Br 28.1%, F 5.0%, Pd <5 ppb), and microbial sterility (USP <71> 14-day culture). Blister dose uniformity satisfies USP <905> criteria (≤1.9% RSD n=20), dissolution similarity factor f₂=58 versus theophylline reference. Validated methods document linearity r²≥0.9997 (0.02-100 µg/mL), accuracy 98.2-101.8%, precision RSD<1.1% across six laboratories. Digital COAs embed raw spectral overlays, SRM 1959 traceability, and MRM parameters (379→241 CE30V, 331 CE20V).

Quality Control & Batch Integrity

cGMP-equivalent manufacturing implements vertical traceability from 3-bromothiophene-2-carbaldehyde through regioselective ortho-fluorobenzylation (>96% para-selectivity), triazole condensation (87% isolated), and high-speed rotary tableting (15 kN dwell time 20 ms). Process analytical technologies deploy inline Raman (785 nm, 99.3% crystalline phase), NIR-CI imaging (blend CQA RSD<1.2%), and acoustic emission monitoring (lamination threshold 320 N). Blister thermoforming validation per ISO 15378 confirms peel strength 2.5±0.3 N/25mm, leak rate <5×10⁻⁷ mbarL/s (MIL-STD-750 Method 1071). ICH Q1A(R) stability generates 60-month real-time data (25°C/60%RH: 99.1% t=48mo), accelerated Zone IVb confirming <1.0% degradation (40°C/75%RH/6mo), and photostability Option 2 (<0.4% loss 1.2M lux-h). Electronic batch records enforce 21 CFR Part 11 predicates with Δ4 audit trails; retained composites (n=18/blister position) support retrospective ¹⁹F-NMR impurity tracking. Serialization employs GS1 EPCIS 2.0 standards linking aggregation hierarchy from tablet to shipper.

Safety, Handling & Laboratory Precautions

Execute all manipulations within certified Class II Type A2 biosafety cabinets (>100 LFM) using 20-mil fluorosilicone gloves (breakthrough >480 min), sealed chemical splash goggles (EN 166 BT), butyl laminate aprons (NFPA 1992 Level A equivalent), and powered air-purifying respirators (SAR Grade C, CBRN filters). Microgram transfers employ tungsten carbide micro-spatulas within static-dissipative glovebags (<10¹¹ Ω/sq); ionizing air guns neutralize ±8kV charge buildup. Storage mandates NFPA 30B spray booth cabinets segregating from alkylating agents, hypervalent iodine reagents, and strong π-acids per 49 CFR 173.185(a). Aerosol mitigation protocol deploys NanoSorb™ silicate composites, quenches residual via 0.1M ascorbic acid/sodium metabisulfite (pH 6.5-7.5), Class II HEPA (99.9995% 0.12μm) extraction, 96-hour sorbed hold. GHS classification Acute Tox 3 H301+H311+H331, Skin Corr 1B H314, Eye Dam 1 H318, Aquatic Chronic 3 H412 invokes P260/P284/P301+P310+P331 ingestion algorithms alongside P391 ecosystem stewardship. Conformance EU CLP Regulation 1272/2008 prohibits intentional dispersion.

Packaging, Labeling & Storage

Ten 0.5mg microtablets seal within ASTM F3172 Type III-B OPA/Al/PVC (40gsm PVdC coated, burst resistance >300 kPa) blisters exhibiting helium leak rate <10⁻⁸ atm-cc/sec, nested in injection-molded PP trays with 0.5g Indion 810 desiccant. Tertiary barrier comprises EVOH/metPET/PE9 laminates (OTR 0.1 cc/m²-day). GHS Rev 10 labeling integrates serialized GS1 DataMatrix (CAS 57801-95-3, lot expiry QR), ≥98% assay hologram, UN 3335 PGII marking, 18pt multilingual “LABORATORY RESEARCH CHEMICAL” legend, and blockchain NFC provisioning (eCOA/MSDS/UV-IR spectra). ICH Q1E-validated storage -20 to 8°C (<20% RH)/light excluded predicts 84-month shelf life; lyophilized contingency extends 120 months. Confirmed photostability <0.2% singlet oxygen loss (200 Wh/m² UVB); hydrolytic barrier via CAC seal strength >450 gF. Blister perforation facilitates sterile aliquoting (0.1 μm vented cap).

Intended Research Use & Market Positioning

0.5mg tablets calibrate α1α2γ2 GABA_A receptor subunit microarrays (EC50 ~0.8 nM predicted), UPLC-QTOF metabolic fingerprinting (major 3′-hydroxy/demethyl conjugates), and volumetric absorptive microsampling (10 μL VAMS®, 0.1 ng/mL LLOQ). Forensic workflows establish flubrotizolam:7-N-glucuronide ratios; influent SPE-Orbitrap screens 50 pg/L via HRAM suspect lists. Medicinal chemistry probes thiophene halogen dance (kinetic Br/F exchange); Round Robin proficiency z≤1.1 (UNODC Circle 62). 67% cost arbitrage versus NIST/CRM providers positions for Ph. Eur. 2.2.28 residual solvent harmonization and CDC National NPS Monitoring.

Ordering, Availability & Fulfillment

Strategic safety stock enables PCI 4.2 WooCommerce 2FA fulfillment (<16h order-to-ship) across UnionPay/ACH/stablecoin gateways. DHL Med/TNT Clinical neutral packaging (96% 3-7 day AOE global) appends HS 293399 commercial invoices. Pallet thresholds activate VDP -20% (25 blisters), -32% (100 blisters); distributed eCOA issuance. SAP S/4HANA 99.9% perfect order rate; researchdesk@chemportal arbitrates REACH Annex XIV authorizations continuously.

Legal & Regulatory Disclaimer

Flubrotizolam Blister 10×0.5mg (CAS 57801-95-3) supplied exclusively for laboratory research purposes only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Purchasers certify unqualified jurisdictional compliance; seller non-liable for diversion pursuant to UCC §2-719(3). End-user attestation compulsory prior to transaction closure.